Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSEARCA:CWEBNYSE:HEXOTSE:LABSNASDAQ:VIR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCWEBDirexion Daily CSI China Internet Index Bull 2x Shares$40.08-5.2%$38.85$24.60▼$59.31$291.38M0.7738,490 shs508,350 shsHEXOHEXO$0.71+2.5%$0.87$0.66▼$3.84$31.24M1.35880,508 shs305,500 shsLABSMediPharm LabsC$0.10-5.0%C$0.09C$0.06▼C$0.12C$39.43M0.88342,404 shs159,980 shsVIRVir Biotechnology$4.55+1.1%$6.02$4.32▼$14.45$628.98M1.361.37 million shs1.23 million shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCWEBDirexion Daily CSI China Internet Index Bull 2x Shares+3.12%+13.37%+25.18%-2.33%+4.19%HEXOHEXO0.00%0.00%0.00%0.00%0.00%LABSMediPharm Labs+5.26%+17.65%+17.65%+53.85%+17.65%VIRVir Biotechnology-4.26%-19.79%-19.21%-53.03%-55.36%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCWEBDirexion Daily CSI China Internet Index Bull 2x SharesN/AN/AN/AN/AN/AN/AN/AN/AHEXOHEXON/AN/AN/AN/AN/AN/AN/AN/ALABSMediPharm LabsN/AN/AN/AN/AN/AN/AN/AN/AVIRVir Biotechnology2.7437 of 5 stars3.41.00.00.02.53.31.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCWEBDirexion Daily CSI China Internet Index Bull 2x Shares 0.00N/AN/AN/AHEXOHEXO 0.00N/AN/AN/ALABSMediPharm Labs 0.00N/AN/AN/AVIRVir Biotechnology 2.86Moderate Buy$32.86622.14% UpsideCurrent Analyst Ratings BreakdownLatest CWEB, LABS, HEXO, and VIR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/12/2025VIRVir BiotechnologyNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$19.00 ➝ $14.004/17/2025VIRVir BiotechnologyThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$28.00 ➝ $21.002/28/2025VIRVir BiotechnologyBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$26.00 ➝ $31.002/28/2025VIRVir BiotechnologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$110.00 ➝ $110.002/27/2025VIRVir BiotechnologyNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$19.00 ➝ $19.00(Data available from 5/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCWEBDirexion Daily CSI China Internet Index Bull 2x SharesN/AN/AN/AN/AN/AN/AHEXOHEXO$146.20M0.21N/AN/A$2.44 per share0.29LABSMediPharm LabsC$39.42M1.00C$0.07 per share1.30C$0.11 per share0.87VIRVir Biotechnology$14.30M43.98N/AN/A$11.82 per share0.38Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCWEBDirexion Daily CSI China Internet Index Bull 2x SharesN/AN/A13.78∞N/AN/AN/AN/AN/AHEXOHEXO-$845.90M-$5.21N/AN/AN/A-235.33%-74.04%-32.51%N/ALABSMediPharm Labs-C$12.05M-C$0.03N/A∞N/A-30.56%-24.41%-7.17%N/AVIRVir Biotechnology-$615.06M-$4.22N/AN/AN/A-678.40%-36.71%-31.00%7/30/2025 (Estimated)Latest CWEB, LABS, HEXO, and VIR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2025Q1 2025VIRVir Biotechnology-$0.83-$0.88-$0.05-$0.88$8.59 million$3.03 million2/26/2025Q4 2024VIRVir Biotechnology-$0.85-$0.76+$0.09-$0.76$8.14 million$12.37 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCWEBDirexion Daily CSI China Internet Index Bull 2x Shares$1.463.64%N/AN/AN/AHEXOHEXON/AN/AN/AN/AN/ALABSMediPharm LabsN/AN/AN/AN/AN/AVIRVir BiotechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCWEBDirexion Daily CSI China Internet Index Bull 2x SharesN/AN/AN/AHEXOHEXO0.010.410.24LABSMediPharm Labs1.453.213.10VIRVir BiotechnologyN/A8.948.94Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCWEBDirexion Daily CSI China Internet Index Bull 2x SharesN/AHEXOHEXO7.78%LABSMediPharm Labs0.71%VIRVir Biotechnology65.32%Insider OwnershipCompanyInsider OwnershipCWEBDirexion Daily CSI China Internet Index Bull 2x SharesN/AHEXOHEXO4.69%LABSMediPharm Labs4.45%VIRVir Biotechnology15.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCWEBDirexion Daily CSI China Internet Index Bull 2x SharesN/A7.27 millionN/ANot OptionableHEXOHEXO1,27744.00 million41.93 millionOptionableLABSMediPharm Labs130415.00 millionN/ANot OptionableVIRVir Biotechnology580138.24 million116.24 millionOptionableCWEB, LABS, HEXO, and VIR HeadlinesRecent News About These CompaniesOrbimed Advisors LLC Reduces Stock Holdings in Vir Biotechnology, Inc. (NASDAQ:VIR)May 15 at 7:52 AM | marketbeat.comVir Biotechnology, Inc. (NASDAQ:VIR) Shares Acquired by Hudson Bay Capital Management LPMay 15 at 5:25 AM | marketbeat.comVir Biotechnology (NASDAQ:VIR) Hits New 52-Week Low After Analyst DowngradeMay 15 at 1:40 AM | americanbankingnews.comVir Biotechnology (NASDAQ:VIR) Given New $14.00 Price Target at Needham & Company LLCMay 14 at 10:07 AM | marketbeat.comVir Biotechnology (NASDAQ:VIR) Price Target Cut to $14.00 by Analysts at Needham & Company LLCMay 13 at 1:56 AM | americanbankingnews.comVir’s hepatitis B combo falls short in Phase II trialMay 12 at 10:46 PM | msn.comVir Biotechnology to Participate in Bank of America Securities 2025 Healthcare ConferenceMay 12 at 4:05 PM | businesswire.comBridgeway Capital Management LLC Sells 66,538 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR)May 12 at 4:46 AM | marketbeat.comVir Biotechnology, Inc. (NASDAQ:VIR) Shares Purchased by Dimensional Fund Advisors LPMay 11, 2025 | marketbeat.comVir Biotechnology First Quarter 2025 Earnings: Revenues DisappointMay 10, 2025 | finance.yahoo.comDAFNA Capital Management LLC Invests $734,000 in Vir Biotechnology, Inc. (NASDAQ:VIR)May 10, 2025 | marketbeat.comWhy Vir Biotechnology, Inc.’s (VIR) Stock Is Down 5.45%May 10, 2025 | aaii.comQ1 2025 Vir Biotechnology Inc Earnings CallMay 10, 2025 | finance.yahoo.comVir's 'functional cure' candidate for hepatitis B misses mark in phase 2May 10, 2025 | fiercebiotech.comVir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH StudyMay 9, 2025 | businesswire.comVir Biotechnology’s Earnings Call: Mixed Sentiment Amid ProgressMay 8, 2025 | tipranks.comVir Biotechnology: Tobevibart Combination Pushing Forward For Needed HDV TreatmentMay 8, 2025 | seekingalpha.comVir Biotechnology announces initiation of ECLIPSE Phase III program for hepatitis delta virusMay 8, 2025 | msn.comVir Biotechnology Inc (VIR) Q1 2025 Earnings Call Highlights: Navigating Challenges with ...May 8, 2025 | uk.finance.yahoo.comVir Biotechnology, Inc. (VIR) Q1 2025 Earnings Call TranscriptMay 7, 2025 | seekingalpha.comVir Biotechnology, Inc. (VIR) Reports Q1 Loss, Lags Revenue EstimatesMay 7, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCWEB, LABS, HEXO, and VIR Company DescriptionsDirexion Daily CSI China Internet Index Bull 2x Shares NYSEARCA:CWEB$40.08 -2.22 (-5.25%) As of 04:10 PM EasternThe Direxion Daily CSI China Internet Bull 2X Shares (CWEB) is an exchange-traded fund that is based on the CSI Overseas China Internet index. The fund provides 2x leveraged daily exposure to an index composed of overseas-listed Chinese internet companies. CWEB was launched on Nov 2, 2016 and is managed by Direxion.HEXO NYSE:HEXOHEXO Corp., together with its subsidiaries, produces, markets, and sells cannabis in Canada. The company offers its adult-use and medical products under the HEXO brand name. It also provides cannabis beverages under the Little Victory, House of Terpenes, Mollo, Veryvell, and XMG brands; and cannabis products under UP Cannabis, Original Stash, and Up brand names. It has a strategic alliance with Tilray Brands, Inc. The company was formerly known as The Hydropothecary Corporation and changed its name to HEXO Corp. in August 2018. HEXO Corp. was founded in 2013 and is headquartered in Gatineau, Canada. As of June 22, 2023, HEXO Corp. operates as a subsidiary of Tilray Brands, Inc.MediPharm Labs TSE:LABSC$0.10 -0.01 (-5.00%) As of 02:25 PM EasternMediPharm Labs Corp, along with its subsidiaries, produces purified, pharmaceutical-like cannabis extracts and related derivative products. The company generates revenue from Private label, White label, the Tolling process, and others. Some of its vape brands are Northern Lights, Blue Dream Pink Kush and GG4. Its geographical segments are Canada and Australia.Vir Biotechnology NASDAQ:VIR$4.55 +0.05 (+1.11%) As of 04:00 PM EasternVir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas An Acquisition Just Made Dick's the Most Exciting Stock in Retail Walmart Stock Alert: Big Price Move Expected Soon Broadcom Set to Surge as AI Diffusion Rule Ends Microsoft and OpenAI Just Hit Reset—Here’s Why MSFT Stock Wins Is Bally’s Turnaround a Safe Bet Amid Mixed Investor Sentiment? SMCI Stock Rally: 45% Gain in 2 Days Could Be Just the Start Intel Makes a Cool Move With Shell, But Will Investors Warm Up? AMD’s AI-Powered Stock Price Rally Just Shifted Gears Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
